Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.
Hubei Goto Biopharm Co.Ltd. (300966) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.90 Billion CNY
Based on the latest financial reports, Hubei Goto Biopharm Co.Ltd. (300966) has total liabilities worth CN¥1.90 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hubei Goto Biopharm Co.Ltd. - Total Liabilities Trend (2017–2024)
This chart illustrates how Hubei Goto Biopharm Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hubei Goto Biopharm Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Hubei Goto Biopharm Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
agilon health Inc
NYSE:AGL
|
USA | $1.14 Billion |
|
Bajaj Hindusthan Sugar Limited
NSE:BAJAJHIND
|
India | ₹86.92 Billion |
|
LUBAWA SA
WAR:LBW
|
Poland | zł151.17 Million |
|
Zhejiang East Asia Pharmaceutical Co. Ltd.
SHG:605177
|
China | CN¥1.57 Billion |
|
Guangdong AVCiT Tech Hldg Co
SHE:001229
|
China | CN¥70.03 Million |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
USA | $46.80 Million |
|
Addcn Technology Co Ltd
TWO:5287
|
Taiwan | NT$1.79 Billion |
|
Loandepot Inc
NYSE:LDI
|
USA | $5.81 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Hubei Goto Biopharm Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Goto Biopharm Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Goto Biopharm Co.Ltd. (2017–2024)
The table below shows the annual total liabilities of Hubei Goto Biopharm Co.Ltd. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.78 Billion | +24.67% |
| 2023-12-31 | CN¥1.42 Billion | +30.98% |
| 2022-12-31 | CN¥1.09 Billion | +183.99% |
| 2021-12-31 | CN¥382.83 Million | +44.69% |
| 2020-12-31 | CN¥264.58 Million | -21.36% |
| 2019-12-31 | CN¥336.43 Million | +62.67% |
| 2018-12-31 | CN¥206.82 Million | +13.09% |
| 2017-12-31 | CN¥182.88 Million | -- |